AIDS CLINICAL TRIALS UNIT

辛辛那提大学艾滋病临床试验中心(UC ACTU)打算 继续为爱滋病临床试验小组作出贡献 项目负责人罗伯特·斯库利，医学博士。 艾滋病临床试验小组是规模最大、最复杂的 世界上的临床试验网络，因此处于独特的地位 同时促进了对艾滋病毒疾病的病理生理认识 制定艾滋病毒感染及其并发症的管理策略。 艾滋病临床试验小组的研究议程将随着 知识库扩大。作为这一进程的参与者，辛辛那提 反恐组将会： 目标1继续进行广泛的临床试验和 次级研究以确保辛辛那提ACTU对 委员会研究议程的目标， 目标#2确定辛辛那提ACTU招收少数族裔的障碍 以及克服它们的方法， 目标#3继续辛辛那提ACTU的研究重点 卡氏肺孢子虫通过将最新的基础科学进展带入 临床试验赛场， 目标#4将辛辛那提大学真菌学中心发展成为 为ACTG研究真菌感染的病理生物学提供资源 临床试验的背景。 目标1将通过每年招收约200名受试者来实现 进入临床试验及其子研究的一年。加州大学ACTU将继续 它在临床试验的收益、保留和数据方面的出色表现 管理层。 目标2将通过制定具体的少数族裔招募计划来实现 有目的、有目的、有可检验的假设。到1997年6月， 项目将生成关于以下各项功效的具体数据 针对少数民族入学的各种干预措施。 目标3将通过继续世界级的活动来实现 由加州大学ACTU在 彼得·沃尔泽博士的指导，包括基础科学家和 临床医生为了一个共同的目标而共同努力。 目标4将通过发展临床/基础科学来实现 利用肺孢子虫研究小组的模型进行合作， 并利用大量成熟的基础设施 真菌学科学家和他们与优秀的临床相结合 加州大学ACTU的项目。

The University of Cincinnati AIDS Clinical Trials Unit (UC ACTU) intends to continue its contributions to the AIDS Clinical Trials Group under the direction of its Project Leader, Robert Schooley, M.D. The AIDS Clinical Trials Group is the largest and most sophisticated clinical trials network in the world, and thus is in a unique position to concurrently advance pathophysiologic understanding of HIV disease while developing management strategies for HIV infection and its complications. The research agenda of the AIDS Clinical Trials Group will change as the knowledge base expands. As a participant in this process, the Cincinnati ACTU will: Aim #1 Continue to perform a broad range of clinical trials and substudies to assure maximum Cincinnati ACTU contribution to the objectives of the ACTG research agenda, Aim #2 Identify barriers to minority enrollment at the Cincinnati ACTU and methods for overcoming them, Aim #3 Continue the research emphasis of the Cincinnati ACTU on Pneumocystis carinii by bringing recent basic science advances into the clinical trials arena, Aim #4 Develop the University of Cincinnati Mycology Center into a resource for the ACTG to study the pathobiology of fungal infection in the context of clinical trials. Aim #1 will be accomplished by enrolling approximately 200 subjects per year into clinical trials and their substudies. The UC ACTU will continue its excellent performance in clinical trials accrual, retention, and data management. Aim #2 will be met by developing a specific Minority Recruitment Program with goals and objectives and testable hypotheses. By June 1997, the project will have generated specific data regarding the efficacy of various interventions for minority enrollment. Aim #3 will be achieved by continuing the activities of the world class Pneumocystis research team that has developed at the UC ACTU under the direction of Dr. Peter Walzer which includes basic scientists and clinicians working together toward a common goal. Aim #4 will be achieved by developing a clinical/basic science collaborative effort using the model of the Pneumocystis research team, and taking advantage of the large number of well established basic scientists in mycology and combining them with the excellent clinical program of the UC ACTU.